The feasibility of a personalized approach to venous thromboembolism prophylaxis in heavier critically ill patients.

Not Applicable

Active, not recruiting

• Conditions: Critical illness; Venous thromboembolism; Blood - Clotting disorders

• Registration Number: ACTRN12622000182796
• Lead Sponsor: Royal Melbourne Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-02
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

I. Adult patients greater than or equal to 18 years of age
II. Admitted to RMH ICU
III. Admission weight recorded as greater than or equal to 100 kg
IV. Suitable to receive VTE chemoprophylaxis with enoxaparin (a Low Weight Molecular Heparin)

Exclusion Criteria

I. Renal impairment that would cause a reduction in chemoprophylaxis dosing (eGFR < 30 ml/min).
II. Admitted after cardiac- neuro- or spinal surgery
III. Pregnancy
IV. Abnormal baseline coagulation (INR >1.5 or APTT >60 sec or platelets <50 × 109/L)
V. Require therapeutic anti-coagulation
VI. Treating intensivist believes either a fixed dose (40mg BD) OR weight-based dynamic adjustment dosing regimen is required for that patient.
VII. Received > 3 doses of enoxaparin in this ICU admission

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measure is feasibility of the weight-based dosing with dynamic adjustment.<br>The feasibility threshold will be set at 5% of anti-Xa levels reaching therapeutic levels (i.e. if the percentage of anti-Xa levels 0.6 IU/mL is less than 5 % of recorded values) the intervention will be deemed feasible. Anti-Xa levels are determined by blood samples drawn. [ Measured throughout the entire duration of the patient's stay in ICU. ]